BGI Genomics Secures Historic 950 Million RMB Genetic Testing Contract in Saudi Arabia
BGI Genomics’ joint venture, Genalive, won a 950 million RMB contract from NUPCO for genetic testing services in Saudi Arabia. This three-year agreement is the largest in NUPCO’s history, covering 930,000 tests across 83 public hospitals. It includes advanced services such as whole genome sequencing and integrates Chinese genomics technology with local healthcare.
BGI Genomics has announced that its joint venture, Genalive, has secured a significant contract worth 950 million RMB from the Saudi National Unified Procurement Company (NUPCO). This contract is part of a three-year centralized procurement project aimed at providing outsourced testing services to public hospitals in Saudi Arabia.
The collaboration during the global pandemic has been pivotal, as BGI Genomics provided extensive nucleic acid testing solutions and virus sequencing platforms. This partnership has enhanced Saudi Arabia’s public health infrastructure and established vital variant monitoring capabilities, contributing significantly to epidemic prevention.
This contract is noteworthy as it represents the largest outsourced testing service agreement for Genalive in Saudi Arabia, thereby bolstering the country’s precision medicine services. It includes a diverse array of testing methodologies such as next-generation sequencing (NGS), pathology, cytogenetics, and Sanger sequencing, totaling 930,000 testing services across 83 public hospitals.
Genalive’s offerings under this contract will encompass whole genome sequencing (WGS), whole exome sequencing (WES), monogenic disease panels, non-invasive prenatal testing (NIPT), hereditary cancer screening, and preimplantation genetic testing (PGT). This comprehensive service model integrates cutting-edge Chinese genomics technology with local healthcare resources, facilitating diagnostics, equipment supply, and technical training.
BGI Genomics, through its joint venture Genalive, has secured a historic contract in Saudi Arabia valued at 950 million RMB for outsourced genetic testing services. This contract enhances Saudi Arabia’s public health capabilities and precision medicine initiatives, underscoring the significance of the partnership in advancing the nation’s healthcare infrastructure.
Original Source: www.biospectrumasia.com
Post Comment